A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
A phase 1/2 trial of Cevostamab, Lenalidomide, Tocilizumab in multiple myeloma, run by Hoffmann-La Roche, now recruiting.
Overview
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma is a phase 1/2 interventional study registered as NCT05583617 by Hoffmann-La Roche, with 200 participants planned, started 2023-11-14 and due to reach its primary completion in 2028-07-31. Interventions recorded: Cevostamab, Lenalidomide, Tocilizumab, Iberdomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi
Shares Cevostamab, Tocilizumab, Roche / Genentech, Multiple myeloma.
- TrialCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Shares Cevostamab, Roche / Genentech, Multiple myeloma.
- TrialA Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly
Shares Iberdomide, Lenalidomide, Multiple myeloma.
- TrialA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe
Shares Iberdomide, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialSafety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Shares Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti
Shares Tocilizumab, Lenalidomide, Roche / Genentech.
- TrialOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants
Shares Iberdomide, Dexamethasone, Multiple myeloma.
- TrialA Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple
Shares Iberdomide, Dexamethasone, Multiple myeloma.